Kepler Capital Keeps Their Hold Rating on GlaxoSmithKline (GSK)
In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
pharmaphorum2d
Immunocore and GSK pick third cancer immunotherapy target
GSK and Immunocore hope the TCRs can prove to be in the ‘third generation’ of immuno-oncology drugs, following on from checkpoint inhibitors such as Merck’s Keytruda and BMS’ Opdivo ...
Nature1y
GSK welcomes partners with innovative technologies to accelerate vaccine R&D
GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...
Benzinga.com3y
GSK (NYSE:GSK) Stock Quotes, Forecast and News Summary
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff ...
MarketWatch1mon
GSK outperforms market despite losses on the day
Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.86% to 8,280.36.
Yahoo Finance7d
GSK’s Nucala Gains Approval in China for CRSwNP
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...
GSK’s GSK’227 receives FDA BTD for treating adults with relapsed osteosarcoma
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...